MMP-7 is a predictive biomarker of disease progression in patients with idiopathic pulmonary fibrosis

ERJ Open Research

Volumn 3, Issue 1, 2017, Pages

  Bauer, Yasmina ^a   White, Eric S ^b   de Bernard, Simon ^c   Cornelisse, Peter ^a   Leconte, Isabelle ^a   Morganti, Adele ^a   Roux, Sebastien ^a   Nayler, Oliver ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b UNIVERSITY OF MICHIGAN   (United States)

^c AltraBio   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C PEPTIDE; FAS LIGAND; MATRILYSIN; OSTEOPONTIN; PROCOLLAGEN TYPE I C PEPTIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FIBROSING ALVEOLITIS; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 85114065337     PISSN: None     EISSN: 23120541     Source Type: Journal    
DOI: 10.1183/23120541.00074-2016     Document Type: Article

References (35)

1. Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT Clinical Practice Guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med 2015; 192: e3-e19.
2. Costabel U, Inoue Y, Richeldi L, et al. Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med 2016; 193: 178-185.
3. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J 2016; 47: 243-253.
4. Kolb M, Collard HR. Staging of idiopathic pulmonary fibrosis: past, present and future. Eur Respir Rev 2014; 23: 220-224.
5. Richards TJ, Kaminski N, Baribaud F, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 185: 67-76.
6. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012; 156: 684-691.
7. Zhang Y, Kaminski N. Biomarkers in idiopathic pulmonary fibrosis. Curr Opin Pulm Med 2012; 18: 441-446.
8. Jenkins G, Goodwin A. Novel approaches to pulmonary fibrosis. Clin Med 2014; 14: Suppl. 6, s45-s49.
9. Kaarteenaho R, Lappi-Blanco E. Tissue is an issue in the search for biomarkers in idiopathic pulmonary fibrosis. Fibrogenesis Tissue Repair 2015; 8: 3.
10. Ley B, Brown KK, Collard HR. Molecular biomarkers in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2014; 307: L681-L691.
11. King TE Jr, Brown KK, Raghu G, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184: 92-99.
12. Kopinski P, Balicka-Slusarczyk B, Dyczek A, et al. Enhanced expression of Fas ligand (FasL) in the lower airways of patients with fibrotic interstitial lung diseases (ILDs). Folia Histochem Cytobiol 2011; 49: 636-645.
13. Pardo A, Gibson K, Cisneros J, et al. Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis. PLoS Med 2005; 2: e251.
14. Rosas IO, Richards TJ, Konishi K, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 2008; 5: e93.
15. Selman M, Pardo A. Idiopathic pulmonary fibrosis: misunderstandings between epithelial cells and fibroblasts? Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 165-172.
16. Borensztajn K, Crestani B, Kolb M. Idiopathic pulmonary fibrosis: from epithelial injury to biomarkers--insights from the bench side. Respiration 2013; 86: 441-452.
17. Peljto AL, Zhang Y, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 2013; 309: 2232-2239.
18. Agnihotri R, Crawford HC, Haro H, et al. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem 2001; 276: 28261-28267.
19. Kadota J, Mizunoe S, Mito K, et al. High plasma concentrations of osteopontin in patients with interstitial pneumonia. Respir Med 2005; 99: 111-117.
20. Boon K, Bailey NW, Yang J, et al. Molecular phenotypes distinguish patients with relatively stable from progressive idiopathic pulmonary fibrosis (IPF). PLoS ONE 2009; 4: e5134.
21. Kuwano K, Hagimoto N, Kawasaki M, et al. Expression of FasL and Fas protein and their soluble form in patients with hypersensitivity pneumonitis. Int Arch Allergy Immunol 2000; 122: 209-215.
22. Kuwano K, Hagimoto N, Kawasaki M, et al. Essential roles of the Fas-Fas ligand pathway in the development of pulmonary fibrosis. J Clin Invest 1999; 104: 13-19.
23. Kuwano K, Kawasaki M, Maeyama T, et al. Soluble form of Fas and Fas ligand in BAL fluid from patients with pulmonary fibrosis and bronchiolitis obliterans organizing pneumonia. Chest 2000; 118: 451-458.
24. Wallach-Dayan SB, Elkayam L, Golan-Gerstl R, et al. Cutting edge: FasL+ immune cells promote resolution of fibrosis. J Autoimmun 2015; 59: 67-76.
25. Ho CY, Lopez B, Coelho-Filho OR, et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med 2010; 363: 552-563.
26. Shahin M, Schuppan D, Waldherr R, et al. Serum procollagen peptides and collagen type VI for the assessment of activity and degree of hepatic fibrosis in schistosomiasis and alcoholic liver disease. Hepatology 1992; 15: 637-644.
27. Leenstra T, Acosta LP, Wu HW, et al. T-helper-2 cytokine responses to Sj97 predict resistance to reinfection with Schistosoma japonicum. Infect Immun 2006; 74: 370-381.
28. Fabre V, Wu H, PondTor S, et al. Tissue inhibitor of matrix-metalloprotease-1 predicts risk of hepatic fibrosis in human Schistosoma japonicum infection. J Infect Dis 2011; 203: 707-714.
29. Box GEP, Cox DR. An analysis of transformations. J Roy Statist Soc Ser B 1964; 26: 211-243.
30. Breen EC, Reynolds SM, Cox C, et al. Multisite comparison of high-sensitivity multiplex cytokine assays. Clin Vaccine Immunol 2011; 18: 1229-1242.
31. King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011; 378: 1949-1961.
32. Loveman E, Copley VR, Colquitt JL, et al. The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation. BMC Pharmacol Toxicol 2014; 15: 63.
33. White ES, Xia M, Murray S, et al. Plasma surfactant protein-D, matrix metalloproteinase-7, and osteopontin index distinguishes idiopathic pulmonary fibrosis from other idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2016; 194: 1242-1251.
34. Coghlan JG, Denton CP, Grunig E, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2014; 73: 1340-1349.
35. Jenkins RG, Simpson JK, Saini G, et al. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet Respir Med 2015; 3: 462-472.